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The risk ofdeveloping a second primary cancer was studied among 171,749 men and 208,192
women whowere reported tothe Danish Cancer Registry between 1943 and 1980. Onlythosewho
survived at least two months wereincluded in theanalysis, and more than 1.7 million person-years
of observation were accrued. Altogether, 15,084 second primary cancers developed, of which
13,231 were in organs other than the initial or adjacent site [relative risk (RR) = 1.01].
Adjustment for possible underreporting of multiple primary cancers increased the RR to 1.24,
which stresses the need fordetailed knowledgeofregistration procedures interpreting results from
cancer registries. The unadjusted RR for all sites increased with time, from 0.94 during the first
decade of follow-up (excluding the first year) to 1.13 among 30-year survivors, whereas the
adjusted RR increased from 1.08 to 1.41. Elevated risks were observed for sites thought to have a
common etiology. Forexample, cancers ofsmoking-related sites were increased in both directions
following cancers ofthe oral cavity, respiratory tract, and urinary organs. For cancers suspected
to have a hormone- or dietary fat-related association, significant reciprocal relationships were
seen among cancers of the endometrium, ovary, and colon. Cancer treatment probably is an
important factor in second cancer development, even whenjudged indirectly in the present study.
For example, radiotherapy may have been responsible for an elevated risk ofsubsequent cancers
of the thyroid, breast, colon, rectum, bladder, and connective tissue in long-term survivors.
Chemotherapy may have increased the risk of subsequent leukemias. Our data further indicate
that cancer patients have no general susceptibility to develop new malignant tumors, although
high rates may be found for particular sites sharing common risk factors. Conversely, the
occurrence ofone cancer does not appear to protect against developing a new cancer.
Development of multiple primary cancers in the same individual constitutes a
constant challenge to the medical profession and scientists working in cancer research.
Should such events be attributed to host susceptibility, could two or more cancers be
due to the same exogenous risk factor, or were the subsequent cancers induced by
previous anticancer therapy?
Previous studies have shown that cancer patients are not a random sample of the
general population, and Schoenberg [1] found that the site and the risk of second
primary cancer development varied considerably by index site. This observation was
recently confirmed in a collaborative study between the National Cancer Institute,
U.S.A., the Connecticut Tumor Registry, and the Danish Cancer Registry [2,3,4]. The
population-based cancer registry may provide new information for the evaluation and
quantification of the risk of second primary cancer development, especially among
long-term survivors. Among the lattergroup, risks associated with medical procedures,
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e.g., radiotherapy, are most likely to be seen. In contrast, etiologic similarities between
cancers of different sites, including host susceptibility, are likely to result in increased
risks that are not dependent on the duration of survival after the first tumor.
Reciprocal associations, i.e., in both directions between sites, would strengthen
hypotheses ofpossible common etiology [5].
The relative risks of developing second primary cancers of specific sites have been
presented in detail elsewhere, according to organ system of the first primary cancer
[4,6-14]. The present paper evaluates the possible influence of underreporting and
draws attention to associations indicating common etiology and to the role that
treatment for the first cancer has for subsequent cancer risk.
MATERIAL AND METHODS
Cancer Registration in Denmark
Since 1943, incident cases of cancer in Denmark have been reported to the Danish
Cancer Registry by hospital departments, pathology institutes, and practicing physi-
cians. Follow-up for vital status is undertaken annually by record linkage with the
National Death Registry. All tumors in the Cancer Registry arecoded and classified in
accordance with a modified version of the Seventh Revision of the International
Classification of Diseases [15]. A conservative attitude has been taken toward
accepting multiple primary cancers with similar morphologies in adjacent organs, and
new tumors arising within the same organ or organ pair are generally not recorded.
Examination of the development of a new independent cancer in paired organs was
thus not possible. Details on the procedures of the Registry have been described
elsewhere [16]. Registration is voluntary but, for practical purposes, reporting of
initial cancers may be regarded as complete and valid [17,18].
The records ofthe Cancer Registry were by means ofrecord linkage compared with
a national patient registry (LPR) holding diagnosis for all patients discharged from
hospitals in Denmark in 1977 [17]. The results ofthat study, as well as from a detailed
study ofcervix cancer patients 1943-1980 [19], were used in order to evaluate possible
underreporting ofmultiple primary cancers.
Study ofMultiple Primary Cancers 1943-80
Persons with multiple primary caiicers were identified by automated record linkage
performed within the Registry and the risk of multiple primary cancer development
determined [4]. All non-melanoma skin cancers, precancerous lesions, and duplicate
notifications of the same tumor were excluded. Patients who survived less than two
months or who developed a second primary cancer within the first two months
following their initial cancer diagnosis were excluded, leaving 364,857 persons with a
single cancer and 15,084 persons with a second primary cancer available for study. A
total of551 third and fourth primary cancers occurred in these individuals but were not
considered in this study. These 379,941 eligible patients, 171,749 men and 208,192
women, were on average followed for five years and accumulated 1,706,736 person-
years of observation. Second primary cancers developed in 4.2 percent of the women
and 3.7 percent ofthe men. In persons with multiple tumors, approximately 92 percent
of the first and 85 percent of the second primary cancers were verified histologically.
Only 4 percent of the second primary cancers were known to the Registry solely from
death certificates.
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Calculation ofRelative Risks
Person-years at risk were calculated from the date of diagnosis of the first primary
cancer (i.e., date of first hospital admission) until the date of diagnosis of a second
primary cancer, death, or December 31, 1980, whichever occurred first. The expected
numbers of second cancers were estimated by applying sex and site-specific incidence
rates for the general population in Denmark to the corresponding person-years of
observation, using a modified version of the program developed by Monson [20]. The
relative risk (RR) was taken as the ratio ofobserved to expected incident cancers and
approximate 95 percent confidence intervals (CI) ofthe RR were computed, assuming
a Poisson distribution of the observed cancers as described by Rothman and Boice
[21].
RESULTS AND DISCUSSION
All Cancers
For both sexes combined, 16,580 second primary cancers were expected, yielding a
deficit of approximately 1,500 cancers (RR = 0.91; 95 percent CI = 0.90-0.92), as
shown in Table 1. The risk of second primary cancer increased significantly with the
time, since diagnosis of the first primary (p < .001 for trend), from RR = 0.9 in
short-term survivors to RR = 1.1 among those living 30 or more years after their initial
primary cancer (Table 2). The present finding corresponds to an annual average
incidence of 8.8 second cancers per 1,000 persons (7.8/1,000 women; 10.9/1,000
men). These findings agree well with other results [22,23,24]; however, a significant 31
percent increased RR of second cancer in Connecticut [3] was not matched by a
similar increase in our investigation. Differences in registration- procedures may
explain some of the discrepant results between Denmark and Connecticut.
The overall deficit ofcancers occurred mainly during the first five years offollow-up
[4]. During this early follow-up period, both the notifying physician and the Registry
would be hesitant to accept and record a new primary cancer, as a large proportion of
such tumors would likely be regarded as misdiagnosed metastases. In Connecticut, no
similar deficit was observed [3]; in fact the 30 percent excess is present throughout all
time intervals since first primary diagnosis. If the observed and expected second
TABLE 1
Observed (0) and Expected (E) Crude and Adjusted Numbers of Second Primary Cancers Among
Both Sexes in Connecticut (1935-1982) and Denmark (1943-1980)
Adjustment Connecticuta Denmarkb Denmarkc
None 0 16,727 15,084 18,523
E 12,797 16,580 16,580
O/E 1.31 0.91 1.12
Excluding
site of 0 12,831 13,231 16,247
initial E 10,428 13,113 13,113
cancer O/E 1.23 1.01 1.24
'From [3]
bFrom [4]
cAdjusted for possible underreporting
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TABLE 2
Relative Risk of Second Primary Cancer Following Any Primary Cancer in Denmark, 1943-1980
Uncorrected Corrected
Year Since
First Primary 0 E RR 0° E RRa
1-9 8,399 8,979.6 0.94 9,710 8,979.6 1.08
10-19 3,458 3,504.0 0.99 4,257 3,504.0 1.22
20-29 1,158 1,187.3 0.98 1,470 1,187.3 1.24
30+ 190 167.6 1.13 236 167.6 1.41
'Number corrected for estimated degree ofunderreporting
cancers of the same site as the index cancer were subtracted, and when excluding
cancers of buccal cavity following a cancer of lip, tongue, and mouth; colorectal
cancers after a colorectal; female genital after an initial female genital; urinary
following another urinary; and a hematological malignancy following a primary
hematological cancer [3], the RR increased to 1.01 in Denmark and was not
significantly different from unity, while the RR in Connecticut decreased from 1.31 to
1.23 (Table 1).
The change of the RR in opposite directions in Connecticut and Denmark indicates
different attitudes to recording of multiple tumors by these two cancer registries,
overreporting ofmultiple primary cancers may thus take place in Connecticut, in contrast
to Denmark, where underreporting may be equally important. It has been possible to
evaluate reporting ofmultiple cancers in Denmark. A similar evaluation ofother Registry
data, including Connecticut's, has to our knowledge not been undertaken.
Table 3 shows the results ofa linkagestudy among cancerpatients known both tothe
Cancer Registry and to the LPR [17]. According to the LPR, 6.8 percent ofthe cancer
patients admitted to hospitals in 1977 had multiple primary cancers, whereas the
Cancer Registry 1943-80 observed 4.0 percent. However, it is important to emphasize
that the LPR is not a cancer registry. This registry holds all discharge diagnoses (20
possible) for every single hospital admission linked to the personal identifying number
provided all Danish inhabitants. Ifa patient had more hospital admissions, no attempt
was made to link the discharge information from the various admissions and thus to
avoid duplications and errors if a diagnosis was revised. Consequently the LPR had to
be edited to simulate a Cancer Registry, and the computerized editing process may
have allowed for too many multiple cases [17]. For example, a patient with a cancer in
TABLE 3
Frequency of Multiple Primary Cancers in Denmark Estimated from the Danish Cancer Registry
1943-80 (CRG), National Patient Discharge Registry 1977 (LPR), and Cervix Cancer Cohort
1943-82 (CCC)
Cancer Case CRG (%) LPR (%) CCC (%)
Single 364,857 (96.0) 15,342 (93.2) 22,779 (91.2)
Multiple 15,084 (4.0) 1,126 (6.8) 2,191 a (8.8)
All 379,941 (100) 16,468 (100) 24,970 (100)
aEstimated, based on scrutiny of 7.5 percent sample of all notified single cervix cancer cases and 35
percent sample ofall notified second primaries after cervix cancer
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the sigmoid colon, with a primary discharge diagnosis ofcolon cancer, may, at a later
admission, have been discharged as a rectal cancer case and thus calculated as a
multiple primary case. Ifthe patient later was admitted with lung metastasis, and the
discharge diagnosis in error stated lung cancer, this too would give rise to a multiple
primary case. The validity of the cancer discharge diagnoses in the LPR is currently
under evaluation.
On theother hand, somesecond primary cancers are not reported to the Registry, as
was demonstrated in a studyofsecond primary cancer within a cohort of24,970 cervix
cancer patients [19]. Diagnostic information on 627 cases with a known second
primarycancer and 1,705 matched controls, with no knowledge ofany othercancer but
the cervix cancer, were evaluated by thorough scrutiny of all hospital and pathology
records available from the date of cervix cancer diagnosis until death or December
1982. Based on these results, 8.8 percent of all cancer patients should have a second
primary cancer, which is more than twice as many as reported to the Registry (Table
3).
In order to evaluate the upper limit of possible underreporting, we applied these
results from the cervix cancer study on the Cancer Registry cohort of single cancer
cases, taking account of time elapsed between the first and second primary cancer
(Table 4). No account of the influence of overreporting of multiple primary cancers
was taken, as the influence would be minor. The largest proportion (7.2 percent oftotal
18.6 percent) ofunreported second primaries (1,337) was observed within the first five
years of observation (the mean observation time of the Cancer Registry cohort). The
total estimated number of unreported second primaries would be 3,439 cases, which
would increase the number of second primary cancers from 15,084 to 18,523. When
applying these corrected observed numbers, the overall RR changes from 1.01 to 1.24,
which is similar to the observed RR (1.23) in Connecticut (Table 1), while the RR by
time since first primary increases from 1.1 to 1.4, 30 years or moreafter the first cancer
(Table 2).
TABLE 4
Possible Underreporting of Multiple Primary Cancer in Denmark 1943-80, Based on Scrutiny of
Sample of Notified Single Cervix Cancer Cases (CCC)
Time Elapsed Since First Tumor
(years)
0-4 5-9 10-19 20-29 30+ Total
CCC "Single"
No. starting interval 1,705 1,629 1,405 802 237 1,705
Unreported second primary 6 6 26 19 4 65
% unreported 0.4 0.6 1.9 2.4 1.7 3.8
Cancer Registry
No. single cases starting interval 379,941 102,664 56,430 18,121 3,699 379,941
Reported second primary 6,831 3,447 3,458 1,158 190 15,084
Unreported second primary 1,337 567 1,044 429 62 3,439
Estimate no. second primary 8,168 4,014 4,502 1,587 252 18,523
Underreporting ofSecond Primary
% in interval 16.4 14.1 23.2 27.0 24.6 18.6
% oftotal 7.2 3.1 5.6 2.3 0.3 18.6
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It must be borne in mind that these figures represent the upper limit ofunderreport-
ing. Furthermore, it is unknown whether they are applicable to the entire Registry
material, as they were derived from underreporting observed in following only one site,
cervix. Differences in registration procedures [16,25] and probably definitions of
second primary cancers between the registries in Denmark and Connecticut thus are
an important factor in evaluation ofdiscrepant results. In view ofthe underreporting of
multiple cancer, the significant elevated RRs of second primary cancers in Denmark
may be regarded as minimum figures, whereas an insignificant elevated RR or
decreased RR is difficult to interpret.
RELATIONSHIPS BETWEEN SITES OF FIRST
AND SECOND PRIMARY CANCERS
The overall risk of a new primary cancer among all cancer patients is composed of
excesses and deficits of various second tumors after different first primary cancers
[6-14]. Thus the constellation of multiple tumors that occurs in individuals with the
same first primary cancer may provide clues to factors that influence risk.
When bidirectional associations appear to be independent of intervals between
TABLE 5
Significant Associations Between Smoking-Related Cancers, Both Sexes, in
Denmark, 1943-80
First Primary Second Primary O/E 95% CI
Lip Mouth 2.4 1.1-4.8
Larynx 0.1 0.0-0.6
Tongue Mouth 12.0 2.4-35.0
Lung 2.5 1.4-4.1
Mouth Lip 6.3 2.5-12.9
Tongue 20.8 6.7-48.6
Esophagus 5.3 2.3-10.5
Lung 2.4 1.6-3.4
Pharynx Larynx 5.1 1.0-14.9
Lung 1.9 1.1-3.2
Larynx Lung 2.6 2.2-3.1
Pancreas 1.7 1.0-2.6
Lung Larynx 3.1 2.0-4.7
Kidney 2.7 2.0-3.6
Bladder 1.6 1.2-2.0
Kidney Bladder 7.1 6.0-8.4
Bladder Lung 1.6 1.4-1.8
Kidney 3.2 2.7-3.8
Pancreas Kidney 2.7 1.1-5.6
Cervix Esophagus 2.0 1.2-3.0
Lung 2.8 2.4-3.2
Kidney 1.4 1.1-1.8
Bladder 3.0 2.5-3.5
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tumor diagnosis, common etiologic factors are suspected. Tobacco smoking appears to
underlie the associations between cancers of the oral cavity and pharynx, esophagus,
respiratory system, urinary tract, pancreas, and cervix [26-31] (Table 5). Not only do
smokers have an increased risk of developing cancer of these sites, but persons who
develop one of these cancers have an increased risk of yet another smoking-related
tumor [4,6,7,8,10,12]. One-third ofall 481 second tumors seen in lung cancer patients
could be considered to be related to smoking, which explains the 20 percent excess of
second primary cancer among lung cancer patients [6].
For cancers of the oral cavity and pharynx, the elevated RR of cancer of adjacent
sites can be attributed to tobacco (and alcohol), and the same applies to the reciprocal
associations between kidney and bladder cancer. However, it is difficult for us to rule
out the influence ofmisdiagnosis and misclassification ofmetastatic spread on the risk
estimates for tumors arising from the same organ system, and host factors may play an
important role in promoting multifocal tumors and predisposing to the influence of
environmental risk factors. The associations between tobacco-related sites and cancer
ofthe cervix may beconfounded by socioeconomic and other characteristics associated
both with smoking and cervical cancer [32].
Nutritional and hormonal factors probably affect the reciprocal associations
observed between cancers ofthe large bowel, breast, and female genital organs (Table
6). Although the associations are weak and misdiagnosis of metastatic spread in the
abdominal cavity could bias results, cancers of the colon, rectum, biliary tract,
pancreas, breast, endometrium, ovary, and prostate may have similar dietary and
nutritional determinants, such as fat intake [33]. However, the biologic mechanisms
involved are not clear, and the suggested relationship with fat for many ofthese sites is
based mainly on evidence from international correlations [34]. Some of these cancers
evolve in hormone-dependent organs, particularly cancers of the breast, corpus uteri,
and ovary, and it has been suggested that the risk for females developing colon cancer
may also be related to endocrine factors [35]. Thus, an association in both directions
between cancer of the colon and cancers of the endometrium and ovary is interesting.
The overall absence of strong bidirectional associations between cancers of these sites
may be due to a weak association with fat [1,22,23], little variation in the diet of the
Danish population, or a possible underreporting ofmultiple primary cancers.
Obesity has been associated with cancers of the endometrium and breast [29],
possibly due to the increased production ofendogenous estrogens [36]. Several studies
show an association between the use of estrogen unopposed by progesterone and
TABLE 6
Reciprocal Associations (RR) Between Cancers of Hormone-Dependent Organs and the Colon among
Females in Denmark, 1943-1980
First Primary Second Primary RR 95% CI First Primary Second Primary RR 95% CI
Breast Colon 1.1 1.0-1.2 Colon Breast 0.9 0.8-1.1
Colon Corpus uteri 1.8 1.3-2.3 Corpus uteri Colon 1.5 1.3-1.7
Colon Ovary 2.6 2.1-3.1 Ovary Colon 1.7 1.3-2.2
Corpus uteri Breast 1.2 1.1-1.4 Breast Corpus uteri 1.0 0.9-1.2
Ovary Breast 1.1 0.9-1.3 Breast Ovary 1.3 1.1-1.4
Corpus uteri Ovary 0.8a 0.6-1.0 Ovary Corpus uteri 2.3 1.7-3.0
'The RR = 2.7 when allowing for hysterectomies (and thus possible oophorectomies) in calculation of
risk.
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endometrial cancer [37]. Some evidence indicates that estrogens may cause breast
tumors, particularly in high-risk individuals [38]. Ovarian cancer has also been linked
to estrogens [39]. In our study, we observed excesses of breast cancer following
endometrial cancer, and an increased risk of ovarian cancer following endometrial
cancer (Table 6). These data are consistent with the hypothesis that hormonal factors,
including endogenous estrogens, may influence tumor development for these cancer
sites.
Ionizing radiation [40] and certain chemotherapeutic drugs [41] used in the
treatment of cancer are known carcinogens. To evaluate the possible influence of
irradiation on second cancer development, we classified index cancer sites as irradiated
if 50 percent or more received radiation, and not irradiated if 10 percent or less were
irradiated (Table 7). Significant risks ofsolid tumors ten years or more after the initial
cancer diagnosis and the risk of subsequent ANLL during the one- to nine-year
follow-up interval are presented, as radiogenic leukemias are known to appear early,
contrary to solid tumors.
A 2.7-fold and a 1.6-fold increased risk ofthyroid and breast cancers, respectively,
was observed following head and neck cancer. The thyroid gland is known to be
TABLE 7
Relative Risks for Solid Tumors in Long-Term Survivors (10+ Years) and Risk of Acute
Non-Lymphocytic Leukemia (ANLL) among 1-9 Years' Survivors Following Frequently and
Infrequently Irradiated First Primary Cancer in Denmark, 1943-1980
Irradiated' Not Irradiatedb
First Primary Site, Second Primary
% Irradiated Cancer RR 95% CI RR 95% CI
Head and neck,c 76% Thyroid 2.7 1.0-6.0 0.8 0.1-2.8
Female breast 1.6 1.0-2.2 1.0 0.8-1.4
ANLL 1.1 0.4-2.5 1.1 0.6-1.8
Genital organs,d 65% Colon 1.2 1.0-1.4 1.0 0.8-1.3
Rectum 1.5 1.2-1.8 1.4 1.1-1.9
Bladder' 2.6 2.2-3.2 0.8 0.5-1.2
Connective tissue 2.5 1.2-4.6 0.7 0.0-3.8
ANLL 1.9 1.1-3.1 1.1 0.6-1.8
Female breast, 69% Salivary gland 3.2 1.3-6.5 0.8 0.0-4.7
Esophagus 1.7 1.0-2.9 1.0 0.4-2.1
Lung 1.7 1.3-2.1 1.0 0.7-1.3
Ovary 1.5 1.2-1.9 0.5 0.2-1.1
Connective tissue 4.2 2.1-7.6 0.7 0.0-3.8
ANLL 2.7 1.9-3.9 1.1 0.6-1.8
Hodgkin's and NHL 64% Lung 1.8 1.0-2.9 1.0 0.7-1.3
Female breast 2.1 1.1-3.5 1.0 0.8-1.4
Bladder 2.6 1.3-4.7 0.8 0.5-1.2
ANLL 8.4 4.0-15.5 1.1 0.6-1.8
as0 percent or more initial cancers irradiated
bl0 percent or less (average 4 percent) received irradiation (primary sites: stomach, small intestine, colon,
liver, gallbladder, and pancreas).
cIncludes cancers ofthe lip, tongue, salivary glands, gum, mouth, pharynx, larynx, and nasal cavities
dIncludes cancers oftestis, cervix, and corpus uteri
'Includes bladder papillomas
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sensitive to radiation, and increased cancer risks have previously been described
following X-rays to the head and neck region [42], treatment for tinea capitis [43], and
among atomic bomb survivors [44]. The breast cancer excess is unlikely to be
attributable to radiation of the head and neck region because in most instances the
breast would not be in or near the therapeutic fields. The same argument would apply
to head and neck cancers following breast irradiation. A bidirectional association
between salivary gland tumors and breast cancer has been described [45,46], but this
was only suggested among long-term survivors in our study [6,9]. However, the
elevated risk of salivary gland tumors following a breast cancer indicates that these
sites share some common etiology.
The relative risks of cancers of the colon (1.2), rectum (1.5), bladder (2.6), and
connective tissue (2.5) following a frequently irradiated genital cancer were not
unexpected, as all these organs are close to the radiation fields used to treat genital
cancers [47]. The RRs for colon and rectal cancer are compatible with those seen for
other irradiated populations, e.g., patients with ankylosing spondylitis and metropathia
hemorrhagica [48,49]. However, common risk factors for genital and gastrointestinal
cancers or misdiagnosed metastases may account for some of the increased risks.
The increased risks of cancers of the esophagus and lung following breast cancer are
consistent with a radiation effect which has been seen in studies of atomic bomb
survivors [50]. It is unlikely that the increased risk of ovarian cancer following breast
cancer is related to castration radiotherapy because only 6 percent of Danish breast
cancer patients received such treatment [51].
Solid tumors were also in excess among long-term survivors with malignant
lymphoma, in particular cancers of the lung, female breast, and bladder (Table 7).
Radiation may have increased the risk of second cancers in some instances, such as
following the inverted Y irradiation for Hodgkin's disease that exposes a large
proportion of the body trunk. Common etiologies and misdiagnoses of lymphatic
infiltrations could also be involved.
Significantly increased RR of ANLL was noted during the first ten years of
follow-up among patients with initial cancers of the genital organs (1.9), female breast
cancer (2.7), and malignant lymphoma (8.4) (Hodgkin's disease, 20.6; NHL, 3.5).
Interestingly, the RR of ANLL remained significantly elevated among long-term
survivors ofbreast cancer (2.3) [9] and malignant lymphoma (Hodgkin's disease, 14.3;
NHL, 7.1) [14].
The induction of acute leukemia, especially ANLL, is a well-known consequence of
radiation [52-54]. The pattern of increased risk of ANLL within the first ten years
after exposure is consistent with previous reports [55] and different from that observed
for solid tumors. The late excesses of ANLL ten years or more after initial diagnosis
may be related to treatment of recurrent disease. For Hodgkin's disease and NHL,
chemotherapy undoubtedly contributed to the increased risk of leukemia as reported
by others [52,56-58]. Our present findings do not allow us to state whether radiation,
chemotherapy, or both are associated with ANLL, but previous studies have indicated
that alkylating agents are much more likely to be responsible for the increased
leukemia risk than is radiotherapy [59].
CONCLUSION
Many factors influence the results from our study on multiple primary cancers in
Denmark. Utilization ofCancer Registry data is subject to differences in reporting and
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coding practices during the years of operation. Medical surveillance, specificity of
diagnostic methods, and local interest as well as changes in risk factors may over the
years modify the risk. Nonetheless, the usefulness of a population-based cancer
registry in a well-defined population for evaluation and quantification of the risk of
second primary cancers is demonstrated. The long period offollow-up allows consider-
ation oftime trends in risk even for rare cancers.
Even iftheoverall riskofa person developing a second cancer at a different site from
the first may be slightly underestimated, this study shows that a RR above 1.3 may be
ruled out when possible underreporting is taken into account. Our results suggest that
cancer patients overall are not at high risk of developing new malignant tumors.
Conversely, the occurrence of one cancer does not appear to protect against the
development ofa new tumor in another organ.
Elevated rates may occur for particular combinations of sites, especially those
related to common risk factors. No specific risk factor could be examined in the present
descriptive study, but several etiologic leads have been suggested or confirmed, i.e.,
cigarette smoking, hormonal and nutritional factors, radiation, and chemotherapy.
Studies of multiple primary neoplasms provide researchers with a strategy to
investigate the exogenous and endogenous determinants of cancer. To increase the
value of the survey data, staffs of population-based cancer registries must give
attention to improvements in registration of multiple cancers in the same individual
and agree to rules that facilitate international comparisons. This is important with a
view to future etiologic studies and to the identification of high-risk cancer patients
who should be monitored closely for the early detection and management of second
primary cancers.
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